English 中文版
Clinical Center
Medical Oncology
Surgery
Gynecologic Oncology
Traditional Chinese Medicine/Integrative Oncology
Radiation Oncology
Anesthesiology
Medical Laboratory

Contact Us

Tel: +86-731-88651900

Fax: +86-731-88651999

Mail: hnszlyy_network@163.com

Add: 283 Tongzipo Road, Yuelu District, Changsha, 410013, Hunan, P.R. China

Home > News > Newsroom

TomoTherapy successfully launched in our hospital

admin2016-01-22from:Hunan Cancer Hospital

Tomotherapy system, TOMO, is the only device of radiation delivery system using computed tomography to treat cancers in the world. Incorporating IMRT, IGRT and DGRT, it is the most advanced device for radiation delivery. It’s unique Tomotherapy, coupled with computed tomography, crosses the limits of traditional accelerators and accomplishes a full 360-degree focus guided by CT, which can treat malignant tumors efficiently, precisely and safely. The development of Tomotherapy is of revolutionary meaning in the history of cancer treatment, solving three major difficulties related to pioneering technologies in the field of precise radiation delivery now and in the future: IMRT, IGRT and ART, opening a new chapter of radiation treatment.

Our hospital introduced the first Tomotherapy system in our province in August, 2015, and put it into clinical use at the end of 2015. Undoubtedly, it is good news for all cancer patients.


1. Advantages of tomotherapy

Highly conformal dose distribution: compared with the normal radiotherapy and IMRT, Tomotherapy can produce more complicated dose distribution required in clinical use, and thus it is much easier to meet the requirement of ideal dose distribution for radiotherapy—Dose Painting, which means both better conformal and evener distributed dose. With the same dose, complications are much lower compared with the traditional radiotherapy, and patients have better tolerance for treatment.

Precise image guidance: Tomotherapy has developed from the basic structure of spiral CT, and with its inherent function of IGRT, it shares the same imaging and treating sources with high calibration. Discrepancies of isocenters between CBCT and treatment may occur for the traditional accelerator is often installed with CBCT to achieve its guiding function. Besides, Tomotherapy with its integrative low-dose(about 1cGy)CT can produce fairly clear 3D images without metal artifact, which can be conveniently used to modify the setups, resulting in precise implementation of well-distributed dose for each treatment.

Wide range of treatment: the range of one setup treatment by Tomotherapy reaches 150cm*60cm diameter volume, whereas the largest fieldsize of the traditional accelerator is limited to 40cm*40cm. TOMO crosses many limits of the traditional accelerator, which is incomparable in treating wide range and multiple metastasis tumors, and its treating effect has been greatly improved.

Diversified Treating mode: The Tomotherapy system introduced by our hospital is Tomo HD, the latest device of Tomo Company, to which a new function—TomoDirect™ has been added on the basis of TomoHiArt. It is a breakthrough in the field of Tomotherapy, which through TomoDirect™ helps implement fixed angle radiation field used in normal accelerator.

With its TomoDirect™, Tomo HD can provide highly conformal dose distribution through its 12 options of fixed treating angles, modulation of MLC and movement of treatment table. It can significantly shorten plan-making optimization time as well as treating time, replace part of IMRT using 3D conformal radiotherapy and fixed radiation angles, and improve the clinical use and efficiency of TomoTherapy.


2. Application of Tomotherapy 

With its incomparable advantages of treating all types of tumors throughout the body, TomoTherapy can be effectively applied to the treatment of nasopharyngeal carcinoma, recurrent nasopharyngeal carcinoma, lung cancer, pleural mesothelioma, esophageal cancer, brain cancer, breast cancer, prostate cancer, whole-body multiple metastatic tumor, radiotherapy for entire brain, spine and body.

Head and neck tumors: nasopharyngeal carcinoma(NPC), recurrent nasopharyngeal carcinoma, carcinoma of the maxillary sinus, laryns cancer, gingival cancer, oral cancer, tonsil carcinoma, thymic carcinoma, oropharyngeal cancer, tongue cancer, retrobulbar tumor, nasal tumors etc.

Thoracic and abdominal tumors: lung cancer, malignant pleural mesothelioma, liver cancer, esophageal cancer, cholangio carcinoma, breast cancer, mediastinal tumor, mediastinal lymph node metastasis, retroperitoneal tumor.

Intracranial tumors: meningioma, metastatic brain tumor, glioma, craniopharyngioma, ependymoma, pineal region tumor, acoustic neuroma, chordoma, neuronal cell tumor, residual of meingioma surgery and other tumors of postoperative recurrence.

Pelvic tumors: prostate cancer, cervical cancer, ovarian cancer, fallopian tube cancer, pelvic metastases, colorectal cancer, bladder cancer, and the primary cell tumor.

Skin cancers: basal cell carcinoma, squamous cell carcinoma, fibrosarcoma etc.

Hematopoietic diseases: central nervous invasion of leukemia, lymphoma.

Bone tumors: osteosarcoma, bone metastases, multiple metastases.

News
Newsroom
Notice
Videos
International
Clinical Service
Departments
Find a Doctor
Experts
Request an Appointment
Research & Education
Cancer Research
Clinical Trials
Selected Publications
Graduate Education
Resident Training
Download Center
Nursing
Nursing
About us
Introduction
Leadership
Contact
Q&A